search
Back to results

Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy

Primary Purpose

Anxiety Disorder, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific

Status
Completed
Phase
Phase 3
Locations
United Kingdom
Study Type
Interventional
Intervention
medical chart review
questionnaire administration
acupressure therapy
quality-of-life assessment
sham intervention
standard follow-up care
Sponsored by
University of Manchester
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Anxiety Disorder focused on measuring nausea and vomiting, anxiety disorder, unspecified adult solid tumor, protocol specific

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS:

  • Diagnosis of any cancer

    • Scheduled to receive their first chemotherapy course
    • Scheduled to receive highly, moderately, or low-emetogenic chemotherapy
    • Scheduled to receive a chemotherapy regimen given as a single administration at the beginning of the course repeated in 3-week courses
  • Currently receiving adjuvant chemotherapy as outpatient
  • Acupressure wristband-naïve (in terms of never having tried such a wristband; may have seen or heard about such wristbands)

PATIENT CHARACTERISTICS:

  • Able to perform self care (i.e., no inability to use wristbands appropriately or mental incapacity preventing continuous and optimal use of wristbands) as judged by the investigators
  • No liver disease
  • No metabolic risk factors for nausea (i.e., electrolyte imbalances causing nausea/vomiting)
  • No mechanical risk factors for nausea (i.e., intestinal obstruction)
  • No nausea and/or vomiting due to use of opioids
  • No lymphedematous arms
  • No chronic alcohol use

PRIOR CONCURRENT THERAPY:

  • No concurrent radiotherapy
  • No concurrent chemotherapy regimens as inpatients

Sites / Locations

  • University of Manchester

Outcomes

Primary Outcome Measures

Incidence and severity of nausea as assessed by the Rhodes Index of Nausea & Vomiting before and after chemotherapy

Secondary Outcome Measures

Incidence and extent of acute and delayed nausea and vomiting by the MASCC Antiemesis Tool at day 10 of each course
Quality of life as assessed by FACT-G at baseline and at day 10 of each course
Anxiety as assessed by the Hospital Anxiety & Depression Scale at baseline
Expectation for nausea and vomiting as assessed by the Patient Expectations of Nausea/Vomiting after each chemotherapy course
Measure of blindness (to intervention vs sham) assessed after chemotherapy
Sociodemographic and treatment characteristics assessed at baseline

Full Information

First Posted
September 15, 2009
Last Updated
August 23, 2013
Sponsor
University of Manchester
search

1. Study Identification

Unique Protocol Identification Number
NCT00978185
Brief Title
Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy
Official Title
The Effectiveness and Cost Effectiveness of Acupressure for the Control and Management of Chemotherapy-related Nausea.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
October 2010 (Actual)
Study Completion Date
October 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Manchester

4. Oversight

5. Study Description

Brief Summary
RATIONALE: Acupressure wristbands may prevent or reduce nausea caused by chemotherapy. It is not yet known whether acupressure wristbands are more effective than standard care in controlling acute and delayed nausea. PURPOSE: This randomized phase III trial is studying acupressure wristbands to see how well they work compared with standard care in controlling nausea caused by chemotherapy.
Detailed Description
OBJECTIVES: Primary To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone. Secondary To assess the cost effectiveness and extent of use of usual care in patients using acupressure wristbands in addition to standard care for the management of chemotherapy-induced nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone. To assess the level of quality of life in patients using acupressure and standard care alone. To assess the clinical effectiveness of self-acupressure using wristbands in addition to standard care in the management of chemotherapy-induced (acute and delayed) vomiting compared to patients receiving standard care with sham-acupressure wristbands and standard care alone. To ascertain for which emetogenic level of chemotherapy regimens (i.e., high, moderate, or low emetogenic chemotherapy) self-acupressure using wristbands in addition to standard care is more or less effective in terms of nausea compared to patients receiving standard care with sham-acupressure wristbands and standard care alone. To ascertain whether any improvement in chemotherapy-induced nausea and vomiting from using acupressure wristbands is different in males and females. To ascertain whether there is an age effect from the use of acupressure wristbands in relation to chemotherapy-induced nausea and vomiting. OUTLINE: Patients are stratified according to gender, age in years (16 to 24 vs >24 to 50 vs > 50), and level of emetogenic chemotherapy (high vs moderate vs low). Patients are randomized to 1 of 3 intervention arms: Arm I (acupressure group): Patients receive standard antiemetics comprising an oral 5-HT3 receptor antagonist (i.e., Zofran) and oral or IV dexamethasone before and for 3 days post-chemotherapy (for highly emetic chemotherapy); an oral 5-HT3 receptor antagonist (i.e., Zofran) and dexamethasone IV before chemotherapy and a 5-HT3 receptor antagonist or dexamethasone for 2 days post-chemotherapy (for moderately emetogenic chemotherapy); or oral dexamethasone before chemotherapy (for low-emetogenic chemotherapy). Beginning on the morning before chemotherapy, patients wear a pair of SeaBand™ elastic wristbands on each arm for 7 days. Each wristband has a 1-cm protruding round plastic button (stud) pressing the P6 acupoint, located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis. Arm II (sham acupressure group): Patients receive standard antiemetics as in arm I. Beginning on the morning before chemotherapy, patients wear a pair of elastic wristbands on each arm for 7 days. Each wristband has a flat button pressing the P6 acupoint, located on the anterior surface of the forearm, approximately three-finger width up from the crease of the wrist between the tendons of the Palmaris longus and flexor carpi radialis. Arm III (control group): Patients receive standard antiemetics as in arm I. Patients are assessed periodically by questionnaires.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety Disorder, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Keywords
nausea and vomiting, anxiety disorder, unspecified adult solid tumor, protocol specific

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 3
Allocation
Randomized
Enrollment
699 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Other
Intervention Name(s)
medical chart review
Intervention Type
Other
Intervention Name(s)
questionnaire administration
Intervention Type
Procedure
Intervention Name(s)
acupressure therapy
Intervention Type
Procedure
Intervention Name(s)
quality-of-life assessment
Intervention Type
Procedure
Intervention Name(s)
sham intervention
Intervention Type
Procedure
Intervention Name(s)
standard follow-up care
Primary Outcome Measure Information:
Title
Incidence and severity of nausea as assessed by the Rhodes Index of Nausea & Vomiting before and after chemotherapy
Secondary Outcome Measure Information:
Title
Incidence and extent of acute and delayed nausea and vomiting by the MASCC Antiemesis Tool at day 10 of each course
Title
Quality of life as assessed by FACT-G at baseline and at day 10 of each course
Title
Anxiety as assessed by the Hospital Anxiety & Depression Scale at baseline
Title
Expectation for nausea and vomiting as assessed by the Patient Expectations of Nausea/Vomiting after each chemotherapy course
Title
Measure of blindness (to intervention vs sham) assessed after chemotherapy
Title
Sociodemographic and treatment characteristics assessed at baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of any cancer Scheduled to receive their first chemotherapy course Scheduled to receive highly, moderately, or low-emetogenic chemotherapy Scheduled to receive a chemotherapy regimen given as a single administration at the beginning of the course repeated in 3-week courses Currently receiving adjuvant chemotherapy as outpatient Acupressure wristband-naïve (in terms of never having tried such a wristband; may have seen or heard about such wristbands) PATIENT CHARACTERISTICS: Able to perform self care (i.e., no inability to use wristbands appropriately or mental incapacity preventing continuous and optimal use of wristbands) as judged by the investigators No liver disease No metabolic risk factors for nausea (i.e., electrolyte imbalances causing nausea/vomiting) No mechanical risk factors for nausea (i.e., intestinal obstruction) No nausea and/or vomiting due to use of opioids No lymphedematous arms No chronic alcohol use PRIOR CONCURRENT THERAPY: No concurrent radiotherapy No concurrent chemotherapy regimens as inpatients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alex Molassiotis, MD
Organizational Affiliation
University of Manchester
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Manchester
City
Manchester
State/Province
England
ZIP/Postal Code
M13 9PL
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Acupressure Wristbands or Standard Care in Controlling Nausea Caused by Chemotherapy

We'll reach out to this number within 24 hrs